Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Leqembi’s April-June Sales Up 2.2-Fold from Prior Quarter: Eisai
August 2, 2024
- Maruho, Meiji to End Co-Promotion of Amenalief in Japan
August 2, 2024
- Toa Eiyo to Downsize Workforce by 100 through Voluntary Buyout
August 1, 2024
- Sumitomo Announces Its Largest-Yet Job Cut of 700 Employees in Japan
August 1, 2024
- SanBio’s Cell Therapy Akuugo Scores Conditional Approval
August 1, 2024
- Daiichi Sankyo’s Q1 Sales Grow 24% as Mainstays Fare Well
August 1, 2024
- Chugai to Develop Roche’s PI3K Inhibitor Inavolisib in Japan
August 1, 2024
- AstraZeneca Files Tagrisso, Imfinzi for Post-Chemoradiation Setting
August 1, 2024
- Twymeeg Champion Trophy Winner in June GP Rep Promotion Rankings: Intage
August 1, 2024
- Local Anesthetic Runs Short in Japan Due to Curbed Supply of Sandoz’ Anapeine
July 31, 2024
- Novo’s Cell Therapy Partner Heartseed Goes Public on TSE
July 31, 2024
- Foreign Pharma Sales in Japan Likely to Fall for 2nd Straight Year in 2024: Fuji Keizai
July 31, 2024
- JCR Ditches Temcell Program for nHIE Indication
July 31, 2024
- Chugai to Practically Scrap Mandatory Retirement Age in 2026
July 30, 2024
- Recordati Japan on Hunt for Rare Disease Assets at Risk of Drug Loss
July 30, 2024
- Astellas Gets EMA Blessing for Gastric Cancer Drug Zolbetuximab
July 30, 2024
- Padcev-Keytruda Nears EU Nod for 1st Line Bladder Cancer
July 30, 2024
- Xocova Grabs Near-70% Share among Oral COVID Meds in Japan: Shionogi
July 30, 2024
- Mitsubishi Tanabe to Launch Voluntary Buyout Program
July 30, 2024
- AZ, United Immunity to Tie Up on Drug Delivery Tech Research
July 29, 2024
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…